The FARAPULSE FARA-Freedom Trial

Inclusion Criteria: * Diagnosis of paroxysmal atrial fibrillation (PAF), AND * Two (2) or more episodes of recurrent PAF during the 6 months preceding the consent Date, AND * At least 1 episode of Atrial Fibrillation (AF) documented with a tracing within 12 months preceding the consent date. * Age 18 years or older * Therapeutic Failure for the treatment of Atrial Fibrillation (effectiveness or intolerance) of at least one active antiarrhythmic drug (AAD) for rhythm control. * Willing and Capable of providing Informed Consent to undergo study procedures AND * Participate in all examinations and follow-up visits and tests associated with this clinical study Exclusion Criteria: * Any previous left atrial (LA) ablation (except permissible retreatment subjects) * Any previous LA surgery * Current intracardiac thrombus (can be treated after thrombus is resolved) * Presence of any pulmonary vein stents * Presence of any pre-existing pulmonary vein stenosis * Body Mass Index (BMI) \>45.0 * Anteroposterior Left Atrial diameter \> 5.5 cm by transthoracic echocardiography (TTE)/ intracardiac imaging (ICE) * Presence of any cardiac valve prosthesis * Clinically significant mitral valve regurgitation or stenosis * Myocardial infarction, percutaneous coronary intervention (PCI) / percutaneous transluminal coronary angiography (PTCA) or coronary artery stenting which occurred during the 3 month interval preceding the Consent Date * Unstable angina * Any cardiac surgery which occurred during the 3 month interval preceding the Consent Date * Any significant congenital heart defect corrected or not (including atrial septal defects or pulmonary vein abnormalities but not including minor PFO) * New York Heart Association (NYHA) class III or IV congestive heart failure * Left ventricular ejection fraction (LVEF) \< 35% * 2º (Type II) or 3º atrioventricular block * Presence of a permanent pacemaker, biventricular pacemaker, atrial defibrillator or any type of implantable cardiac defibrillator (with or without biventricular pacing function) * Hypertrophic cardiomyopathy * Active Systemic infection * Uncontrolled hyperthyroidism * Any cerebral ischemic event (strokes or TIAs) which occurred during the 6 month interval preceding the Consent Date. * Any woman known to be pregnant * Solid organ or hematologic transplant, or currently being evaluated for an organ transplant * Severe lung disease, pulmonary hypertension, or any lung disease associated with chronic abnormal blood gases or requiring supplemental oxygen * Renal insufficiency with an estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2, or any history of renal dialysis or renal transplant * Active malignancy, or history of treated malignancy within 24 months of enrollment (other than cutaneous basal cell or squamous cell carcinoma) * Life expectancy less than one (1) year * Current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of this study (data collection for registries or retrospective studies is permitted) * Unwilling or unable to comply fully with study procedures and follow-up * Clinically significant psychological condition that in the Investigator's opinion would prohibit the subject's ability to meet the protocol requirements * Other uncontrolled medical conditions that may modify device effect or increase risk, including uncontrolled diabetes mellitus, untreated sleep apnea or active alcohol abuse